Home » Stocks » EOLS

Evolus, Inc. (EOLS)

Stock Price: $9.06 USD 0.40 (4.62%)
Updated May 14, 2021 4:00 PM EDT - Market closed
Market Cap 477.76M
Revenue (ttm) 58.29M
Net Income (ttm) -136.88M
Shares Out 37.10M
EPS (ttm) -3.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $9.06
Previous Close $8.66
Change ($) 0.40
Change (%) 4.62%
Day's Open 8.72
Day's Range 8.66 - 9.22
Day's Volume 946,677
52-Week Range 2.85 - 17.38

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Q1 2021 Net Revenues of $12.2 million, Despite Half-Quarter ITC Impact

4 days ago - GlobeNewsWire

Evolus Inc (NASDAQ: EOLS) has announced two newly published peer review studies in Aesthetic Surgery Journal that provide supportive evidence of the safety and efficacy of repeat doses of prabotulinumto...

4 days ago - Benzinga

Evolus (EOLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

6 days ago - Zacks Investment Research

With the trading day about halfway over, the broad markets were somewhat mixed. The Dow Jones industrial average and S&P 500 each posted a handy gain, while the Nasdaq was barely in the red.

Other stocks mentioned: ALL, BKNG, CYBR, HLT, CC, KTOS, RARE
1 week ago - 24/7 Wall Street

NEWPORT BEACH, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced ...

1 week ago - GlobeNewsWire

Evolus, Inc. (EOLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

Few are smiling about the company's upcoming share issue.

3 weeks ago - The Motley Fool

NEWPORT BEACH, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS) announced today the pricing of its public offering of 9,000,000 shares of its common stock at a public offering pric...

3 weeks ago - GlobeNewsWire

NEWPORT BEACH, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS) announced today that it has commenced a proposed underwritten public offering, subject to market and other condition...

3 weeks ago - GlobeNewsWire

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -231.82% and -0.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Q4 2020 Net Revenue $20.6 Million, Highest Net Revenue Quarter Since Launch of Jeuveau ®

1 month ago - GlobeNewsWire

Evolus Inc (NASDAQ: EOLS) has announced that its strategic partner Daewoong Pharmaceutical Co. Ltd will pay Evolus $25.5 million in cash and eliminate $10.5 million of current and potential future miles...

1 month ago - Benzinga

NEWPORT BEACH, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announce...

1 month ago - GlobeNewsWire

Pro Forma Cash Position of $57 Million at December 31, 2020 1

1 month ago - GlobeNewsWire

NEWPORT BEACH, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today an...

2 months ago - GlobeNewsWire

Evolus (EOLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

2 months ago - Zacks Investment Research

NEWPORT BEACH, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today ann...

2 months ago - GlobeNewsWire

With the trading day more than halfway over, the broad markets have pushed higher, seemingly recovering from Tuesday.

Other stocks mentioned: ANF, MAT, WDC, ALLK, EBS, GBIO, RDUS ...
2 months ago - 24/7 Wall Street

Evolus (EOLS) stock was on the rise Friday following news that it's no longer dealing with lawsuits from AbbVie (ABBV) and Medytox. The post EOLS Stock: The Big News That Has Evolus Shares Skyrocketing ...

2 months ago - InvestorPlace

NEWPORT BEACH, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today ann...

2 months ago - GlobeNewsWire

Novavax (NASDAQ: NVAX) shares are trading higher Friday after the company announced a Memorandum of Understanding with Gavi to provide 1.1 billion cumulative doses of NVX-CoV2373. Novavax is a biotechno...

Other stocks mentioned: NVAX, VCNX
2 months ago - Benzinga

Evolus Inc (NASDAQ: EOLS), AbbVie Inc (NYSE: ABBV), and Medytox announced settlement agreements to fully resolve all outstanding litigation, including the United States International Trade Commission (I...

Other stocks mentioned: ABBV
2 months ago - Benzinga

NORTH CHICAGO, Ill. and NEWPORT BEACH, Calif. and SEOUL, Feb. 19, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV), Evolus (NASDAQ: EOLS) and Medytox announce settlement agreements to fully resolve all outstand...

Other stocks mentioned: ABBV
2 months ago - PRNewsWire

Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

Section 337 Violation Partially Affirmed by ITC

4 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - December 15, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Evolus, Inc. (NASDAQ: EOLS) ("Evolus" ...

5 months ago - Newsfile Corp

NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Evolus, Inc. (NASDAQ: EOLS) between February 1, 2019 and July 6, 20...

5 months ago - GlobeNewsWire

BENSALEM, Pa., Dec. 14, 2020 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming December 15, 2020 deadline to file a lead plaintiff motion in the class action filed on beha...

5 months ago - PRNewsWire

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Evolus, Inc. ("Evolus” or "the Company") (NASDAQ: EOLS) and certain of...

5 months ago - Business Wire

Los Angeles, California--(Newsfile Corp. - December 14, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Evolus, Inc. (...

5 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - December 14, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Evolus, Inc. (NASDAQ: EOLS) between February 1, 2019...

5 months ago - Newsfile Corp

Investors with losses in excess of $1,000,000 are encouraged to contact the firm before December 15, 2020; click here to submit trade information Investors with losses in excess of $1,000,000 are encour...

5 months ago - GlobeNewsWire

Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $250,000 In Evolus To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - Dec...

5 months ago - Newsfile Corp

Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $250,000 In Evolus To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - Dec...

5 months ago - Newsfile Corp

NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United S...

5 months ago - GlobeNewsWire

LOS ANGELES--(BUSINESS WIRE)---- $EOLS #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming December 15, 2020 deadline to file a lead plaintiff motion in the class action fil...

5 months ago - Business Wire

Los Angeles, California--(Newsfile Corp. - December 11, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Evolus, Inc. (...

5 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - December 10, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Evolus, Inc. (...

5 months ago - Newsfile Corp

LOS ANGELES, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 15, 2020 deadline to file a lead plaintiff motion in the class action filed ...

5 months ago - GlobeNewsWire

NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, has filed a federal securities class action in the United State...

5 months ago - GlobeNewsWire

Los Angeles, California--(Newsfile Corp. - December 9, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Evolus, Inc. (NA...

5 months ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)-- #ClassAction--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United Sta...

5 months ago - Business Wire

Los Angeles, California--(Newsfile Corp. - December 8, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Evolus, Inc. (NA...

5 months ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Evolus, Inc. (NASDAQ: EOLS) between February 1, 2019 and July 6, 2020, inclusive (th...

5 months ago - Business Wire

Los Angeles, California--(Newsfile Corp. - December 7, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Evolus, Inc. (NA...

5 months ago - Newsfile Corp

Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Evolus To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - Dec...

5 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - December 4, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Evolus, Inc. (NASDAQ: EOLS) between February 1, 2019 ...

5 months ago - Newsfile Corp

Investors with losses in excess of $1,000,000 are encouraged to contact the firm before December 15, 2020; click here to submit trade information

5 months ago - GlobeNewsWire

NEW YORK, Dec. 3, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Evolus, Inc. ("Evolus" or the "Company") (NASDAQ: EOLS). The class a...

5 months ago - PRNewsWire

NEW YORK, Dec. 1, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Evolus, Inc. (NASDAQ: EOLS) between February 1, 2019 and July 6, 2020, i...

5 months ago - PRNewsWire

About EOLS

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Feb 8, 2018
CEO
David Moatazedi
Employees
119
Stock Exchange
NASDAQ
Ticker Symbol
EOLS
Full Company Profile

Financial Performance

In 2020, Evolus's revenue was $56.54 million, an increase of 61.89% compared to the previous year's $34.93 million. Losses were -$163.01 million, 81.1% more than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for Evolus stock is "Buy." The 12-month stock price forecast is 17.11, which is an increase of 88.85% from the latest price.

Price Target
$17.11
(88.85% upside)
Analyst Consensus: Buy